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In the intensive care unit (ICU), there is a high proba-
bility of infection due to resistant pathogens. When
patients develop infections caused by more than one
type of resistant bacteria, it is hard to find optimal
antibiotics to cure the disease. In practice, physicians
have been trying to prescribe antibiotics effectively
according to reliable culture results. However, multi-
ple antibiotic administration is usually accompanied
by much fluid accumulation, which could be a problem
for a critically ill elderly patient with compromised car-
diorespiratory or renal function. Facing the requirement
for infection management, tigecycline, a novel gly-
cylcycline antibiotic, has a broad spectrum including
vancomycin-resistant enterococci (VRE) and multiple-
drug resistant (MDR) Acinetobacter species. It can be
efficiently used to deal with ventilator-associated pneu-
monia (VAP) and can also minimize the amount of
water administered for dissolving multiple antibiotics.
In view of the superiority of tigecycline in this kind of
situation, we report a case of a critically ill elderly man
with infection caused by MDR Acinetobacter baumannii
and VRE, who clinically improved after being treated
with tigecycline.
Case Report
A 75-year-old man with bronchiectasis and chronic
obstructive pulmonary disease complicated by cor pul-
monale and type 2 diabetes mellitus accepted medical
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care in the ICU because of septic shock induced by VAP.
He was treated with empiric antibiotics, hemodynamic-
guided therapy, inotropic agents, and mechanical 
ventilation. Later, sputum yielded MDR Acinetobacter
baumannii that was only susceptible to colistin, and
the central venous catheter tip culture yielded VRE, on
hospital days 5 and 11, respectively. In accordance with
the culture results and septic shock status, the patient
was administered an antibiotic regimen comprising
imipenem, sulbactam, colistin and linezolid for 18 days.
During this period, the daily fluid input and output was
around 4,000 mL and 1,500 mL, respectively. However,
he developed episodes of cyanosis, hypoxemia with
respiratory distress under 90% oxygen inspiration and
mechanical ventilation support with pressure control
of 24 cmH2O, bradycardia, and hypotension accompa-
nied by increasing production of purulent sputum 
and size of pulmonary consolidation on a chest X-ray
(Figure). At that time, his APACHE II score was 42 and 
C-reactive protein level was 26.03 mg/dL. Because ini-
tial antibiotics failed to improve his clinical condition,
the antibiotic regimen was changed to tigecycline and
ceftazidime under the preliminary diagnosis of acute
respiratory distress syndrome complicated by VAP and
pulmonary edema. Stress doses of hydrocortisone and
diuretics were also administered. Two days later, his
body temperature was around 36oC, heart rate was 92
beats per minute, respiratory rate was 24 inspirations
per minute, white blood count was 6,800/μL, blood
pressure was within the normal range without vasopres-
sor support, C-reactive protein level was 3.28 mg/dL,
oxygenation was sufficient with 40% oxygen inspiration
and mechanical ventilation support with pressure
control of 24 cmH2O, the pulmonary consolidation
size was decreased (Figure), and APACHE II score was
22. For four more days, the patient’s edema resolved
because the daily water output became more than 
the input (3,000 mL vs. 2,000 mL per day, respectively).
Unfortunately, on day 29, he suddenly developed sinus
bradycardia, hypotension and a decreased level of con-
sciousness. Cardiogenic shock was suspected, but the
patient did not receive any further invasive interven-
tion before passing away in hospice care at his family’s
request.
Discussion
Infection caused by MDR pathogens is a common
problem in the ICU1,2. However, it is still a requirement
to deal with infection caused by MDR Acinetobacter
baumannii and VRE. Agents frequently reported as
being effective for treating MDR Acinetobacter bau-
mannii include imipenem/cilastatin, colistin, ampicillin/
sulbactam, amikacin, rifampin, and tetracyclines3. Those
currently approved for treating VRE are quinupristin/
dalfopristin, linezolid, and tigecycline4. The success rate
of these antibiotics in treating pneumonia caused by
MDR Acinetobacter baumannii has been reported to
vary from 25% to 93%5, while for pandrug-resistant
Acinetobacter baumannii, success is only around 40%6.
The clinical response rate of quinupristin/dalfopristin
for VRE was reported to be 70.5%6,7 and that for line-
zolid was 92.6%4. Although a recent study indicated
A B
Figure. Size of pneumonia consolidation decreased after antibiotics were changed from imipenem, sulbactam, colistin and
linezolid to tigecycline.
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that combination carbapenem-sulbactam therapy sig-
nificantly decreased the minimal inhibitory concen-
tration of carbapenem for treating pandrug-resistant
Acinetobacter baumannii, it has been shown that there
is no significant difference in clinical outcome from
patients treated with traditional combination regi-
mens8. These clinical results are still disappointing to
physicians. In addition, none of the regimens can deal
with infection caused by MDR Acinetobacter baumannii
and VRE at the same time.
Selection of antibiotics should be based on the
principle of de-escalation, which implies starting with a
broad spectrum antibiotic regimen and then tailoring
the individual therapy based on culture results and local
hospital antibiograms9–11. Tigecycline, a novel glycyl-
cycline antibiotic, which has bacteriostatic effects for
multiple resistant pathogens including VRE, methicillin-
resistant Staphylococcus aureus, extended-spectrum 
β-lactamase-producing Enterobacteriaceae and MDR
Acinetobacter species, may be an additional choice in
this situation12,13. It is normally used to treat skin and
soft tissue infections, and intra-abdominal infections,
with success rates of 90% and 86.6%, respectively14.
However, there is still minimal evidence for the use of
tigecycline in nosocomial pneumonia caused by MDR
Acinetobacter baumannii13,15,16. In a preliminary study,
Schafer et al. reported that symptoms resolved in 84%
of patients who were administered tigecycline to treat
VAP caused by MDR Acinetobacter baumannii15. In addi-
tion, the success rate of tigecycline in treating infection
caused by MDR Acinetobacter baumannii and VRE has
not been well established. Here, we report a unique
case of a patient gaining clinical improvement after
treatment with tigecycline for both MDR Acinetobacter
baumannii VAP and VRE catheter-related infection.
In addition to the bacteriostatic effect of tigecycline,
the lower cost and less fluid accompanying antibiotic
administration of this agent make it a much better
choice than traditional medications (Table). For exam-
ple, treating a patient infected by MDR Acinetobacter
baumannii and VRE with tigecycline costs US$108 per
day and results in 100 mL accompanied fluid adminis-
tration per day because of antibiotic dilution, in contrast
to imipenem/cilastatin, sulbactam and colistin for MDR
Acinetobacter baumannii, costing around US$245 per
day with 800 mL fluid per day, and linezolid for VRE at
US$115 per day with 600 mL fluid per day. Obviously,
tigecycline is more cost-effective and more convenient
for daily fluid balance control.
In conclusion, as patients in the ICU usually have
compromised cardiopulmonary status and may have
infection caused by MDR Acinetobacter baumannii and
VRE, the benefits of tigecycline, with a broader anti-
resistant microbial spectrum, lower cost and easier fluid
balance control than traditional regimens, make it a
better choice in this field, especially as classical regi-
mens are ineffective in improving the clinical condi-
tion. Here, we report a case of a critically ill elderly
man with underlying cardiopulmonary disease, MDR
Acinetobacter baumannii VAP, and VRE catheter-related
infection, with improved clinical condition after being
treated with tigecycline.
Table. The dose, cost and fluid requirement of antibiotics against highly resistant Acinectobacter or enterococci*
Dose for normal 
Cost per bottle (US$) Daily cost (US$)
Fluid required for 
renal function drug dilution (mL)
Tigecycline 50 mg q12h 54.28 (50 mg) 108 100
Imipenem/Cilastatin 0.5 g q6h 33 (0.5 g)† 132 400
Sulbactam 1 g q6h 7.8 (0.5 g) 62.4 400
Piperacillin/Tazobactam 3.375 g q6h 18 (3.375 g)† 72 400
Ceftazidime 2 g q8h 21–28.93 (2 g)† 63–84 300
Amikacin 7.5 mg/kg q12h 34.26 (0.5 g)† 68.52 200–400
Colistin 80–160 mg q8h 17 (150 mg) 51 300–600
Quinupristin/Dalfopristin 5–7.5 mg/kg q8h 138 (350 mg) 300–350 300 (central line); 
750 (peripheral line)
Linezolid 600 mg q12h 82 (600 mg) 115 600
Tigecycline 50 mg q12h 54.28 (50 mg) 108 100
*Adapted from reference 17; †new brand. q12h = every 12 hours; q6h = every 6 hours; q8h = every 8 hours.
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